Compare Mesoblast Limited (MESO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sirius XM Holdings Inc — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Sirius XM Holdings Inc trades at $30.16 (market cap $10.30B). The key difference: Sirius XM Holdings Inc is far larger — about 4.7× Mesoblast Limited's market cap, and Sirius XM Holdings Inc pays a 3.53% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SIRI | |
|---|---|---|
Market Cap | $2.17B | $10.30B |
Sector | Technology | Media |
52-Week High | $20.96 | $31.22 |
52-Week Low | $12.88 | $19.92 |
Enterprise Value | $2.17B | $19.97B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Sirius XM (SIRI) trades at $30.68, up 0.29% with a bullish technical signal and strong analyst support (58% buy ratings). The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a 2024 loss. Recent developments include a strategic advertising partnership with YouTube and potential inclusion in the S&P MidCap 400 index.
The stock presents value characteristics with a P/E of 12.96 and P/B of 0.88, trading near the consensus price target of $31.17. Key risks include competitive pressures in media streaming and high debt levels despite recent improvement. Revenue stabilization and new partnerships provide catalysts, though execution risks remain in a challenging advertising environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
